Literature DB >> 27145125

Correction: Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells.

.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0149995.].

Entities:  

Year:  2016        PMID: 27145125      PMCID: PMC4856372          DOI: 10.1371/journal.pone.0155281

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


The first author’s name appears incorrectly in the article citation. The correct citation is: Wittenberg Dreazen A, Azar S, Klochendler A, Stolovich-Rain M, Avraham S, Birnbaum L, et al. (2016) Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells. PLoS ONE 11(2): e0149995. doi:10.1371/journal.pone.0149995. Table 1 appears incorrectly in the published article. The last six rows are duplicates of the six above them. Please see the correct Table 1 and its caption below. The publisher apologizes for the error.
Table 1

List of proteins that selectively interact with unphosphorylatable form of rpS6.

Whole cell extract from HEK293 cells infected with pS6[5S]-GFP, pS6[5A]-GFP, pS6[5D]-GFP or pEGFP-N1, was subjected to GFP pull-down, and the bound proteins were size fractionated by SDS-polyacrlamide gel electrophoresis. Mass spectrometric analysis of proteins in each lane was performed as described in “material and Methods” and proteins, selectively bound to pS6[5A]-GFP in two independent experiments, are presented (numbers separated by slash [/] represent results obtained in each of the two individual analyses).

Gene nameProteinFunctionLocationAreaaCoveragebNo. of unique peptidesc
PSIP1PC4 and SFRS1-interacting protein 1 (LEDGF)Repair of DNA double-strand breaksNucleus1.141E6/1.705E75.28/17.553/8
TOP2BTopoisomerase (DNA) II betaDNA replication, transcription and repairNucleus7.922E6/2.783E719.62/8.9818/7
SRSF4Serine/arginine-rich splicing factor 4SplicingNucleus2.327E6/3.816E77.89/11.543/2
ABCD3ATP-binding cassette, sub-family D (ALD), member 3Transporter (?)Peroxysomal and mitochondrial membranes1.584E6/9.683E66.83/3.953/2
NDUA9NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 9Accessory subunit of Complex IMitochondria5.180E5/8.213E68.49/9.283/3
SYQGlutaminyl-tRNA synthetaseTranslationCytoplasm1.596E6/5.299E66.32/5.424/3

a Area—displays the average area of the three unique peptides with the largest peak area, based on extracted ion currents (XICs).

b Coverage—displays the percentage of the protein sequence covered by identified peptides.

c No. of unique peptides—Displays the number of peptide sequences unique to a protein group.

List of proteins that selectively interact with unphosphorylatable form of rpS6.

Whole cell extract from HEK293 cells infected with pS6[5S]-GFP, pS6[5A]-GFP, pS6[5D]-GFP or pEGFP-N1, was subjected to GFP pull-down, and the bound proteins were size fractionated by SDS-polyacrlamide gel electrophoresis. Mass spectrometric analysis of proteins in each lane was performed as described in “material and Methods” and proteins, selectively bound to pS6[5A]-GFP in two independent experiments, are presented (numbers separated by slash [/] represent results obtained in each of the two individual analyses). a Area—displays the average area of the three unique peptides with the largest peak area, based on extracted ion currents (XICs). b Coverage—displays the percentage of the protein sequence covered by identified peptides. c No. of unique peptides—Displays the number of peptide sequences unique to a protein group.
  1 in total

1.  Phosphorylated Ribosomal Protein S6 Is Required for Akt-Driven Hyperplasia and Malignant Transformation, but Not for Hypertrophy, Aneuploidy and Hyperfunction of Pancreatic β-Cells.

Authors:  Avigail Dreazen Wittenberg; Shahar Azar; Agnes Klochendler; Miri Stolovich-Rain; Shlomit Avraham; Lea Birnbaum; Adi Binder Gallimidi; Maximiliano Katz; Yuval Dor; Oded Meyuhas
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.